Skip to main content
Pay Bill Portals

Feasibility of adjuvant therapy guided by circulating tumor DNA-based molecular residual disease (ctDNA-MRD) for stage II-III gastric cancer

Published Date

Liu L, Li S, Qu H, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Download PDF